Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 17, 2026
AbCellera Biologics (ABCL) Climbs +76% Over 30 Days on Phase 2 Data

AbCellera Biologics (ABCL) Climbs +76% Over 30 Days on Phase 2 Data

Key Takeaways

  • AbCellera Biologics shares gained approximately 76% over the 30-day period through the latest available close, rising from $6.47 on July 17, 2026, to $11.38 on August 14, 2026.
  • The decisive catalyst was positive Phase 2 data for ABCL635, an investigational antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause.
  • A roughly $200 million follow-on equity offering and a new T-cell engager collaboration with Vertex Pharmaceuticals (VRTX) strengthened the company's funding position and platform validation.
  • Second-quarter revenue declined year over year and the net loss widened, but investors focused on pipeline progress and the company's extended cash runway.
  • Over the trailing quarter, the stock rose roughly 181% from the May 19, 2026 close of $4.05, reflecting a powerful but volatile multi-month uptrend.

Company Overview: AbCellera Biologics and Its Market Position

AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines. Its platform combines technology, data science, infrastructure, and interdisciplinary teams to address challenging antibody discovery problems across endocrinology, women's health, immunology, oncology, and other therapeutic areas.

The company's most advanced internal programs include ABCL635, an antibody candidate for vasomotor symptoms associated with menopause, and ABCL575, an antibody candidate with potential applications in inflammatory and autoimmune conditions. AbCellera also licenses its T-cell engager platform to partners and has built a pipeline of internal discovery programs. Investors follow the stock for its clinical readouts, partnership economics, and the potential for milestone and royalty revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

ABCL Stock Performance: The Last 30 Days Versus the Quarter

Over the last 30 days, ABCL moved from a closing price of $6.47 on July 17, 2026, to $11.38 on August 14, 2026, a gain of approximately 76%. The move was concentrated in mid-August, with daily trading volume expanding sharply as clinical data and financing news reached the market.

The trailing-quarter trend is even stronger. From the May 19, 2026 close of $4.05 to the August 14, 2026 close of $11.38, the stock rose roughly 181%. The path was not linear: shares climbed to $8.12 by June 29, pulled back to $5.31 by July 24, and then surged following the ABCL635 Phase 2 readout. From what I see, the volatility highlights both the risks and the momentum in this name.

Key Catalysts Behind the Recent 30-Day Gains

The primary catalyst was the Phase 2 readout for ABCL635. The company reported that the antibody reduced hot flash frequency by 83% in a study of 92 postmenopausal women, compared with a 33% reduction in the placebo group. Severity scores improved by 58% versus 12% for placebo, and the safety profile was generally favorable, with headache, fatigue, and injection-site reactions among the most common adverse events.

The data triggered analyst repricing. Truist Securities raised its price target to $30 from $12, Cantor Fitzgerald lifted its target to $12 from $11, Stifel increased its target to $9 from $8, and Piper Sandler initiated coverage with a buy rating, according to published analyst notes.

Funding and partnership news amplified the move. AbCellera completed a roughly $200 million follow-on equity offering and announced a collaboration with Vertex Pharmaceuticals (VRTX) to develop multispecific T-cell engagers for autoimmune diseases, with Vertex paying $28 million upfront and funding research and development costs. These developments addressed balance-sheet concerns while adding a new platform partnership.

Drivers Behind the Stronger Quarterly Performance

The quarterly trend reflects a broader shift in the investment narrative from partnership-driven revenue toward internal clinical assets. In June, AbCellera announced a T-cell engager collaboration with Jazz Pharmaceuticals (JAZZ) for gastrointestinal cancers and other solid tumors, including $56 million in upfront payments for the first two programs and up to $792 million per program in potential milestones.

After a mid-summer pullback that took shares below $5.50 in late July, the August ABCL635 data, the Vertex agreement, and the equity offering restored upward momentum. The move also reflected increased investor attention on the company's women's health opportunity and its ability to generate non-dilutive funding through platform deals. One thing that stands out is how quickly sentiment shifted once the clinical and partnership pieces aligned.

What to Watch Next for ABCL

The most important upcoming factors for ABCL include additional ABCL635 data, regulatory planning, and the company's ability to advance the program toward late-stage development. Management has identified a large addressable population, with roughly 12 million women in the United States experiencing moderate-to-severe vasomotor symptoms and more than six million seeking treatment, according to company estimates.

Other watch items include top-line Phase 1 data for ABCL575 expected in the fourth quarter of 2026, progress on ABCL688 and ABCL386 through IND-enabling activities, and the advancement of T-cell engager programs with Vertex Pharmaceuticals (VRTX) and Jazz Pharmaceuticals (JAZZ). Investors should also monitor cash runway, clinical and regulatory risk, placebo response in vasomotor symptom studies, revenue lumpiness, competitive dynamics, and broader biotechnology sector sentiment. I’m watching this closely as the next data points could further clarify the trajectory.

Using AI Tools for Market Insights

In my view, tools like Tickeron’s AI Trend Prediction Engine can add useful context when evaluating momentum in names such as ABCL. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. These resources help surface patterns that might otherwise go unnoticed in fast-moving sectors.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ABCL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


ABCL sees MACD Histogram crosses below signal line

ABCL saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 31, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 37 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ABCL moved out of overbought territory on September 18, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 21 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

ABCL broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on ABCL as a result. In 74 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

Following a +11.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in 205 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 118 of 155 cases where ABCL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.568) is normal, around the industry mean (25.929). P/E Ratio (11.976) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (53.191) is also within normal values, averaging (437.043).

The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.2B. The market cap for tickers in the group ranges from 58 to 128.84B. VRTX holds the highest valuation in this group at 128.84B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 7%. NRSN experienced the highest price growth at 1,794%, while LGVN experienced the biggest fall at -66%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 108%. For the same stocks of the Industry, the average monthly volume growth was 48% and the average quarterly volume growth was -48%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
ABCL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Details
Industry
N/A
Address
150 W 4th Avenue
Phone
+1 604 559-9005
Employees
562
Web
https://www.abcellera.com
Interact to see
Advertisement
TME shares fell over 20% today, with the stock sliding from the mid‑$15s toward the low‑$13s in the wake of its Q4 2025 report and earnings call, extending a pre‑market drop of roughly 12–13%.
HUYA shares fell over 11% today, dropping from the mid‑$3 range toward the low‑$3s following the company’s Q4 2025 earnings release before the U.S. market open. Q4 total net revenues rose about 16% year over year to roughly CNY 1.74 billion, with full‑year 2025 revenues up around 7% to CNY 6.5 billion, but the market had already priced in a rebound after a difficult 2024.​
CWCO fell over 9% today, trading around the low‑$31 range versus recent levels in the mid‑$30s to near $39, as the market reacted negatively to Q4 2025 results and forward commentary. Full‑year 2025 results showed stable earnings and dividend growth but a roughly 9% decline in services revenue to about $46.3 million, reflecting a slowdown in project‑based construction work.
SMTC shares dropped over 8% today after the company reported Q4 results that met or modestly beat Street estimates but showed the slowest year‑over‑year revenue growth in several quarters, at about 9.3% to roughly $274–275 million.
AXTI shares slipped more than 6% today, reversing part of a powerful rally that had recently driven the stock to a 52‑week high above $47 and more than doubled its price year‑to‑date. Q4 2025 revenue of about $23.0 million missed consensus by roughly $1.2 million and fell 8–18% year over year and sequentially, while the company posted another GAAP net loss of around $3.5 million (–$0.08 per share).
Shares of SailPoint, Inc. (SAIL) are tumbling approximately 12% in premarket trading on March 18, 2026, after the company released its fiscal fourth-quarter and full-year 2026 results before the market opened. While Q4 revenue came in slightly above consensus at $295 million (+23% year-over-year), investors were rattled by disappointing forward guidance for fiscal 2027.
Shares of KC surged approximately +17% in premarket trading on March 18, 2026, from a prior close of $13.12 to approximately $15.35. The primary catalyst is Kingsoft Cloud's release of its unaudited Q4 and full-year 2025 financial results before the U.S. market open, which appear to have significantly exceeded analyst expectations.
AngloGold Ashanti (AU) shares tumbled approximately 7% in premarket trading on March 18, 2026, extending a multi-week downtrend that has erased nearly 20% of the stock's value since late January highs. The primary catalyst driving the decline is persistent investor concern over AngloGold's lowered 2026 production guidance, with the company projecting gold output of 2.80–3.17 million ounces — a roughly 3% decline from its 2025 production of 3.1 million ounces.
AAOI shares surged approximately 10.90% in premarket trading on March 18, 2026, rising from a prior close of $86.33 to $95.74. The primary catalyst is strong positive sentiment generated at OFC 2026 — the Optical Fiber Communications Conference and Exhibition — where Applied Optoelectronics unveiled breakthrough laser and transceiver technology for next-generation AI data center infrastructure.
LITE shares surged approximately +12% in early Wednesday trading on March 18, 2026, with the stock changing hands near $727 compared to a prior session close of $649.56. The primary near-term catalyst is Lumentum's S&P 500 index inclusion, effective March 23, 2026, triggering front-running by institutional investors and mandatory buying by passive index funds.
Shares of New Era Energy & Digital, Inc. (NUAI) are trading down approximately 17% during today's session, with the prior close sitting at $5.56. The decline follows the company's March 17 business update conference call and webcast, held after market hours, during which management discussed the recently filed fiscal year 2025 annual report (Form 10-K).
Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.
A jump in the Producer Price Index from 0.3% to around 0.7% month‑over‑month signals that wholesale inflation is re‑accelerating, delaying Fed rate‑cut hopes and reviving the “higher for longer” rates narrative.business. Likely winners in this environment include energy and commodity producers (XOM, CVX, TTE, COP), inflation‑resilient financials (JPM, BAC), and real‑asset plays like pipelines and infrastructure, which can pass through higher prices; ETFs like XLE, XOP, XLF, DBA, GLD offer diversified exposure.
BGSI fell more than 11% today, pulling back from recent levels around the high‑$150s as investors reassessed the risk‑reward following the Q4 2025 print and major U.S. expansion plans. Full‑year 2025 sales rose 2.4% to US$3.14 billion, but same‑store sales declined 0.2%, while reported net earnings fell 25% to US$18.4 million due to US$22.6 million in acquisition and transformation costs.
NG shares fell over 11% today, giving back a portion of steep gains that had taken the stock from near US$2.30 a year ago to recent highs around US$14.40 before the latest pullback. The decline follows a cluster of Donlin‑related announcements — including selection of Fluor as Bankable Feasibility Study (BFS) contractor and an infrastructure/energy letter of intent — which, while positive, highlighted the scale, cost and timeline of the project rather than near‑term cash generation.
SA dropped over 9% today, sliding from around US$30–31 toward the high‑US$27 range in morning trading, as recent optimism about a near‑term KSM partnership met renewed focus on execution and valuation risk. Recent analysis has highlighted that Seabridge’s 2026 “report card” allocates 55% of management’s performance weighting to KSM‑related goals, with securing a JV partner given the single largest weight at 30%, underscoring how concentrated the investment thesis has become.
CABO shares fell over 11% today, sliding from the low‑US$110s toward the US$100 area, extending a brutal 12‑month decline of roughly 55% and bringing the stock closer to the bottom of its 52‑week range near US$70. Q4 2025 results showed a 6.1% year‑over‑year revenue drop to US$363.7 million, with residential data revenue down 4.2% and business data off 1.3%; full‑year revenue fell to about US$1.5 billion from US$1.6 billion in 2024.
In a market rattled by geopolitical tension, tariff uncertainty, and Fed rate volatility, one category of stocks continues to electrify traders: penny stocks, microcaps, and small-caps. These sub-$5 shares can surge 50%, 100%, or even 150% in a single session on a news catalyst — but without the right tools, most retail traders get caught on the wrong side. Enter Tickeron's two powerhouse AI robots: the Small-Cap Stocks - AI Trend Trader 60min (FA) and the Penny Stock - MicroCap Signal Bot 60min (FA).
Elite Returns in a Volatile Sector — Both robots delivered annualized returns above 94%, outperforming the vast majority of active semiconductor funds. High Consistency — Win rates of 68–71% mean these robots win more often than they lose — a rare edge in a sector famous for violent swings.
Exceptional Returns: +79.13% annualized return on a starting balance of $8,040.74, demonstrating consistent alpha generation in the comms-tech sector. High Win Rate: 59.43% of trades close in profit, with a Profit Factor of 2.65 — meaning every $1 risked historically returns $2.65.